1. Introduction {#sec1-jcm-09-00503}
===============

Hyponatremia is the most common electrolyte disorder among hospitalized patients, particularly among the elderly and women, and in the presence of comorbidities \[[@B1-jcm-09-00503],[@B2-jcm-09-00503],[@B3-jcm-09-00503],[@B4-jcm-09-00503],[@B5-jcm-09-00503],[@B6-jcm-09-00503]\]. Its prevalence varies from 8% to 51%, and it often occurs as an acute disease complication, as a chronic disease decompensation, or as a consequence of interventions during patient treatment \[[@B1-jcm-09-00503],[@B5-jcm-09-00503],[@B6-jcm-09-00503]\]. Hyponatremia is a predictor of poor prognosis in various diseases, including heart failure, coronary syndrome, liver cirrhosis, chronic kidney disease, and stroke \[[@B3-jcm-09-00503],[@B5-jcm-09-00503],[@B7-jcm-09-00503],[@B8-jcm-09-00503],[@B9-jcm-09-00503]\]. It is featured on clinical assessment scales, such as APACHE (Acute Physiology and Chronic Health disease classification system) \[[@B10-jcm-09-00503]\] and PSI (Pneumonia Severity Index) \[[@B11-jcm-09-00503]\]. However, whether hyponatremia has a direct effect on mortality, or whether it is a severity marker in certain patients, is unknown \[[@B3-jcm-09-00503]\]. Prognostic factors in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) include baseline disease severity, frequency and severity of exacerbations, age, various comorbidities, history of previous admissions for AECOPD, severity of exacerbations, and a series of physiological and laboratory parameters, such as lung function, respiratory rate at admission, hypoxemia, and hypercapnia \[[@B12-jcm-09-00503],[@B13-jcm-09-00503]\]. Although previous studies show that hyponatremia, particularly when severe, is a predictor of poor prognosis in chronic obstructive pulmonary disease (COPD) \[[@B2-jcm-09-00503]\], few studies determine the prevalence and impact of hyponatremia on the prognosis in the patients with AECOPD requiring hospitalization.

The aim of this study was to establish the prevalence of hyponatremia in patients admitted for AECOPD, as well as its association with poor clinical progress, including prolonged stay, death during hospitalization, or readmission within one month after discharge.

2. Materials and Methods {#sec2-jcm-09-00503}
========================

Prospective observational study carried out from 1 October 2016 to 1 October 2018 in the following hospitals: Salnés in Vilagarcía de Arousa, Arquitecto Marcide in Ferrol, and the University Hospital Complex of Santiago de Compostela, Galicia, Spain, on the patients admitted for AECOPD who had agreed to participate and signed informed consent. COPD diagnosis, baseline severity, and exacerbation were defined according to the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) criteria \[[@B14-jcm-09-00503]\]. Baseline dyspnea was classified as per the extended Medical Research Council Dyspnoea (eMRCD) scale \[[@B15-jcm-09-00503]\]. Comorbidity was assessed using the Charlson Index \[[@B16-jcm-09-00503]\], and history of stroke, atrial fibrillation (AF), chronic heart failure (CHF), arterial hypertension (AHT), ischemic heart disease (IHD), cancer, cognitive impairment, chronic kidney disease (CKD), and anemia were recorded. Patients who had not smoked for over a year at the time of admission were considered former smokers \[[@B17-jcm-09-00503]\]. Patients were divided into four groups by body mass index (BMI) as per the WHO standards: underweight (BMI \< 18.5), normal weight (18.5 ≤ BMI \< 25), overweight (25 ≤ BMI \< 30), and obesity (BMI ≥ 30). Patient baseline treatment was identified, including hyponatremia-inducing drugs, such as thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), non-steroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, carbamazepine, and lamotrigine. The use of at least 5 mg prednisone for three or more consecutive months was considered chronic corticosteroid treatment \[[@B18-jcm-09-00503]\].

Vital signs, arterial blood gas, and chest X-rays were obtained upon patient arrival at the Emergency Department (ED). Complete blood count and serum biochemistry data obtained in both the ED and the hospitalization ward were recorded. Patients were considered to have hyponatremia at admission if serum sodium levels were below 135 mEq/L \[[@B2-jcm-09-00503]\] in at least one of the tests performed from arrival at the ED to hospital discharge. Serum sodium was applied a correction factor of 2.4 for every 100 mg/dL increase in glucose concentration in patients with blood glucose \>200 mg/dL \[[@B19-jcm-09-00503]\]. Hyponatremia severity was categorized into 3 groups: mild (130--134 mmol/L), moderate (120--129 mmol/L) and severe (\<120 mmol/L) \[[@B20-jcm-09-00503]\]. Patients with hypernatremia, defined as serum sodium levels above 145 \[[@B21-jcm-09-00503]\], were excluded from the analysis to avoid confounding factors between high serum sodium and poor progress. Patients with prolonged stay were identified as those with a stay equal to or greater than the median stay of the study population (in our case, 7 days) \[[@B22-jcm-09-00503]\]. Causes of death were classified into 4 groups according to origin: (1) respiratory; (2) cardiovascular (IHD, CHF, and pulmonary embolism); (3) cancer; (4) other causes (septic shock, bronchial aspiration, unknown origin, ...).

Poor progress was defined as follows: prolonged stay, death during hospitalization, or readmission within one month after the index episode discharge.

All the patients in the study signed an informed consent, and the study was approved by the Clinical Research Ethics Committee of Galicia (code 2016/460).

Statistical Analysis
--------------------

The data obtained through statistical analysis are expressed as mean values ± standard deviation (SD) in continuous variables, and as frequencies and percentages in categorical variables. Continuous variables were compared using the Student's *t*-test or the Wilcoxon test; for categorical variables, the chi-square test and the Fisher's exact test were used. Variables independently related to hyponatremia were identified by logistic regression, including those with *p* ≤ 0.05 in the univariate analysis. Variables associated with *p* \< 0.05 were considered statistically significant. All analyses were completed with SPSS 15.

3. Results {#sec3-jcm-09-00503}
==========

A total of 602 patients were enrolled in the study; patient mean age was 73.8 years (SD 10.6) and 86% were male. 65 cases of hyponatremia (10.8%) were recorded, 53 of a mild nature (mean 132.6; SD 1.12), and 12 of a moderate nature (mean 126; SD 2.28). Of all the patients, 362 (60%) featured poor progress: 18 (3%) died at admission; 327 (54.3%) had a prolonged stay; and 91 (15.1%) were readmitted within one month after discharge. The most frequent cause of death was respiratory (53%). Baseline characteristics of the patients are shown in [Table 1](#jcm-09-00503-t001){ref-type="table"}. Patients with worse prognosis were more frequently assigned GOLD Severe and Very Severe grades (*p* \< 0.0001), had worse baseline dyspnea (*p* \< 0.0001), higher percentage of flu vaccination, and higher AF (*p* 0.002), CHF (*p* 0.001), and CKD (0.002) frequency. Regular treatments are shown in [Table 2](#jcm-09-00503-t002){ref-type="table"}. Of the patients, 47.7% received potentially hyponatremia-inducing treatments. Patients with poor progress were more frequently treated with short-acting bronchodilators (SABA (short-acting β2 agonists) (*p* 0.003); SAMA (short-acting anticholinergics) (*p* 0.04), chronic oral corticosteroids (*p* 0.005), theophylline (*p* 0.03), azithromycin (*p* 0.02), acetylcysteine (*p* 0.02), phosphodiesterase inhibitors (*p* 0.01), and home O~2~ (*p* 0.008), although these results were not maintained upon the multivariate analysis.

The most frequent cause of AECOPD had a viral origin, although that was more common in the patients with poor progress (*p* \< 0.0001); they also demonstrated a higher heart rate (0.02), higher leukocytosis (*p* 0.04), higher neutrophilia (*p* 0.02), more cases of hyponatremia (*p* 0.005), and troponin elevation (*p* 0.01); higher urea, potassium, and PCO~2~ levels (*p* 0.001, *p* 0.01 and 0.001, respectively), higher frequency of pneumonia episodes (*p* 0.001), admission to the ICU (*p* 0.01), mechanical ventilation (*p* 0.02), and non-invasive mechanical ventilation (*p* 0.003). Patients with favorable progress had lower PO~2~ (*p* 0.009) ([Table 3](#jcm-09-00503-t003){ref-type="table"}). The history of the patients with hyponatremia featured a higher frequency of AF (*p* 0.005), pleural effusion (*p* 0.01), higher leukocytosis (*p* 0.02), prolonged stay (*p* 0.01), and poor progress (*p* 0.01) ([Table 4](#jcm-09-00503-t004){ref-type="table"}), and the relationship between hyponatremia and AF, pleural effusion and prolonged stay was maintained after the multivariate analysis ([Table 5](#jcm-09-00503-t005){ref-type="table"}). The factors independently associated with poor progress were hyponatremia, pneumonia, and not receiving home O~2~ treatment prior to admission ([Table 6](#jcm-09-00503-t006){ref-type="table"}).

4. Discussion {#sec4-jcm-09-00503}
=============

In our study, the prevalence of hyponatremia in patients admitted for AECOPD is 10.8% higher than that of patients with community-acquired pneumonia as reported by Cuesta et al. \[[@B1-jcm-09-00503]\], but lower than that of patients hospitalized for different causes, including AECOPD \[[@B2-jcm-09-00503],[@B3-jcm-09-00503],[@B4-jcm-09-00503],[@B23-jcm-09-00503],[@B24-jcm-09-00503]\]. In addition to the low prevalence of hyponatremia, the absence of moderate and severe cases also seems noteworthy, despite the high percentage of patients with risk factors to develop it (heart failure, chronic kidney disease, cancer, and certain treatments).

In our study, factors related to poor progress were hyponatremia, pneumonia, and not being home oxygen users. We also observed some differential characteristics between patients with hyponatremia and those with normal sodium levels: the former demonstrate higher prevalence of AF, chest X-ray with pleural effusion, and prolonged stay, and these associations were independent. The higher prevalence of AF in patients with hyponatremia could be explained by its arrhythmogenic capacity, appearing as a result of a series of changes in the electrical activity and properties of the sinus node and pulmonary veins \[[@B25-jcm-09-00503],[@B26-jcm-09-00503]\]. Recent studies show pleural effusion on chest X-ray in 33%--50% of the patients admitted for acute heart failure, and pleural effusion associated with a high rate of adverse events after hospital discharge (readmission, new heart failure episode, or death) \[[@B27-jcm-09-00503],[@B28-jcm-09-00503]\]. In our case, there was a history of heart failure in 30% of the patients, and pleural effusion was recorded in 12%. Although no relationship between pleural effusion and poor progress was found, almost 22% of the patients with hyponatremia also had pleural effusion. Compensatory mechanisms counteracting the low cardiac output include stimulation of the renin-angiotensin-aldosterone system, sympathetic nervous system and release of vasopressin, which contribute to an increase in blood volume and, therefore, to hyponatremia and pleural effusion \[[@B29-jcm-09-00503]\].

Results of the previous studies with the same sodium level cutoff to define hyponatremia (\< 135 mEq/L) are similar to ours. Chalela et al. associate hyponatremia with longer hospital stay and higher hospital mortality in patients admitted for AECOPD \[[@B2-jcm-09-00503]\]. Al Mawed et al. report that hyponatremia is independently associated with hospital mortality and increase in dependence or need for care after discharge, regardless of the diagnosis leading to admission, including AECOPD \[[@B24-jcm-09-00503]\]. The risk of readmission within the first 30 days after discharge due to an episode of heart failure was significantly higher in patients with persistent hyponatremia, regardless of the heart failure severity \[[@B30-jcm-09-00503]\].

Pneumonia is an independent factor of poor prognosis in patients with COPD and has been associated with longer average stay and lower survival \[[@B31-jcm-09-00503],[@B32-jcm-09-00503]\]. Apart from that, hyponatremia occurs in 8%--31% of adults with pneumonia, it can be mild and asymptomatic \[[@B33-jcm-09-00503]\], and it is associated with adverse outcomes, such as higher hospital mortality, the need for intensive care, and longer average stay \[[@B1-jcm-09-00503],[@B34-jcm-09-00503],[@B35-jcm-09-00503]\]. Causality of hyponatremia and pneumonia is uncertain, although the syndrome of inappropriate antidiuretic hormone (ADH) secretion seems to play an important role in this association \[[@B1-jcm-09-00503]\]. Other contributing factors could include the loss of volume and sodium through lungs and skin as a result of hyperventilation and temperature in patients with pneumonia, or adrenal suppression due to corticosteroid treatment---even inhaled---frequent in patients with COPD \[[@B36-jcm-09-00503]\].

In our study, continuous home oxygen therapy (HOT) reduces the risk of poor prognosis. Although HOT is known to increase survival, reduce admission rates and improve the quality of life in patients with COPD and chronic respiratory failure \[[@B37-jcm-09-00503],[@B38-jcm-09-00503]\], the relationship between HOT and patient progress following an AECOPD episode is not clearly defined. Recent literature shows apparently contradictory results in the relationship between HOT and prognosis after AECOPD: mortality, admission rate and average stay increase according to some studies \[[@B39-jcm-09-00503],[@B40-jcm-09-00503],[@B41-jcm-09-00503]\]; and patients with HOT would show higher survival rates after admission to ICU and lower admission numbers according to other authors \[[@B42-jcm-09-00503],[@B43-jcm-09-00503]\].

Better progress of patients requiring HOT could be explained by stricter medical follow-up, allowing for base treatment optimization, health education strengthening, and therapy compliance improvement, consequently impacting progress in a beneficial manner \[[@B44-jcm-09-00503],[@B45-jcm-09-00503],[@B46-jcm-09-00503]\]. It could also allow for early identification of exacerbations, optimizing early management \[[@B47-jcm-09-00503],[@B48-jcm-09-00503],[@B49-jcm-09-00503]\] Patients with HOT have been observed to have lower acidosis during exacerbations --which is an indicator of the lower severity of acute episodes-- than those not requiring HOT \[[@B42-jcm-09-00503]\]. Other pathophysiological mechanisms --not sufficiently clarified yet-- have also been identified, such as the impact on certain mitochondrial genes by HOT in patients with COPD, which could explain these differences in outcome \[[@B50-jcm-09-00503]\].

This study has several limitations. The cause of hyponatremia was not established. The fact that we only had mild and moderate cases of hyponatremia did not allow us to verify the impact of sodium levels on clinical results. Treatments aimed at correcting hyponatremia were not evaluated. The observational nature prevents the study from establishing causality and excluding residual confounding factors.

In conclusion, it seems that hyponatremia is relatively frequent in patients admitted for AECOPD, and it has prognostic implications. Therefore, patients with hyponatremia should be carefully monitored.
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jcm-09-00503-t001_Table 1

###### 

Baseline characteristics of patients.

  Characteristics            Good Progress    Poor Progress    *p*
  -------------------------- ---------------- ---------------- -------
  Age                        73.7 (SD 10.2)   73.9 (SD 10.9)   NS
  Male                       201 (83.8%)      317 (87.6%)      NS
  Institutionalized          7 (3%)           11 (3%)          NS
  FEV1%                      52.9 (SD 18.1)   52.8 (SD 19.5)   NS
  GOLD                                        \<0.0001         
   1                         33 (15.1%)       21 (6.5%)        
   2                         100 (45.7%)      114 (35.3%)      
   3                         51 (23.3%)       81 (24.9%)       
   4                         35 (16%)         109 (33.5%)      
  Phenotype                                   NS               
   Emphysema exacerbator     37 (15.7%)       59 (17.2%)       
   CB exacerbator            63 (26.8%)       119 (34.7%)      
   Non-exacerbator           102 (43.4%)      125 (36.4%)      
   Mixed                     33 (14%)         40 (11.7%)       
  BMI                                         NS               
   Underweight               37 (15.4%)       67 (18.2%)       
   Normal weight             48 (20%)         81 (22.4%)       
   Overweight                83 (34.6%)       123 (34.1%)      
   Obesity                   72 (30%)         90 (24.9%)       
  Tobacco use                                 NS               
   Active smoker             74 (31.2%)       88 (25.7%)       
   Former smoker             148 (62.4%)      226 (65.9%)      
   Never smoker              15 (6.3%)        29 (8.5%)        
  Baseline dyspnea                            \<0.0001         
   1                         7 (3%)           12 (3.4%)        
   2                         68 (29%)         44 (12.6%)       
   3                         94 (40%)         94 (26.9%)       
   4                         46 (19.6%)       113 (32.4%)      
   5a                        18 (7.7%)        68 (19.5%)       
   5b                        2 (0.9%)         18 (5.2%)        
  Flu-vaccinated             142 (59.2%)      255 (70.8%)      0.003
  Charlson                   6.1 (SD 26.1)    5.4 (SD 2.6)     NS
  Stroke                     21 (8.8%)        38 (10.5%)       NS
  AF                         48 (20%)         113 (31.2%)      0.002
  CHF                        53 (22.1%)       128 (35.4%)      0.001
  AHT                        134 (55.8%)      223 (61.6%)      NS
  IHD                        39 (16.3%)       70 (19.3%)       NS
  DM                         58 (24.2%)       88 (24.3%)       NS
  Cancer                     45 (18.8%)       93 (25.6%)       NS
  Cognitive impairment       9 (3.8%)         26 (7.2%)        NS
  CKD                        19 (7.9%)        61 (16.9%)       0.002
  Anemia                     25 (10.4%)       57 (15.7%)       NS
  Admissions previous year   0.7 (SD 1.2)     0.9 (SD 1.4)     NS
  ED previous year           1.1 (SD 1.7)     1.2 (SD 2.0)     NS

AF: atrial fibrillation; AHT: arterial hypertension; BMI: body mass index; CB: chronic bronchitis; CHF: chronic heart failure; CKD: chronic kidney disease; DM: diabetes mellitus; ED: emergency department; FEV1%: Tiffeneau--Pinelli index; IHD: ischemic heart disease; NS: not significant
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###### 

Baseline treatment of patients.

  Drug                           Good Progress   Poor Progress   *p*
  ------------------------------ --------------- --------------- -------
  SABA                           80 (33.3%)      164 (45.3%)     0.003
  LABA                           187 (77.9%)     281 (77.6%)     NS
  IC                             143 (59.6%)     239 (66%)       NS
  Oral C.                        6 (2.5%)        29 (8%)         0.005
  SAMA                           40 (16.7%)      85 (23.5%)      0.04
  LAMA                           158 (65.8)      240 (66.3%)     NS
  Theophylline                   17 (7.1%)       45 (12.4%)      0.03
  Beta blocker                   47 (19.6%)      60 (16.6%)      NS
  Diuretic                       94 (39.2%)      154 (42.5%)     NS
  Azithromycin                   3 (1.3%)        16 (4.4%)       0.02
  Acetylcysteine                 12 (5%)         37 (10.2%)      0.02
  Antileukotrienes               5 (2.1%)        9 (2.5%)        NS
  Phosphodiesterase inhibitors   5 (2.1%)        22 (6.1%)       0.01
  Home O~2~                      43 (17.9%)      99 (27.3%)      0.008
  Hyponatremia-inducing drugs    119 (49.6%)     168 (46.4%)     NS

IC: inhaled corticosteroid; LABA: long-acting β2 agonists; LAMA: long-acting anticholinergics; NS: not significan; Oral C.: chronic oral corticosteroid; SABA: short-acting β2 agonists; SAMA: short-acting anticholinergics;
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###### 

Exacerbation characteristics.

  Clinical Data           Good Progress      Poor Progress      *p*
  ----------------------- ------------------ ------------------ -------
  Cause of Exacerbation                      \<0.0001           
  Viral                   44 (18.3%)         26 (7.2%)          
  Bacterial               168 (70%)          292 (80.7%)        
  Non-infectious          28 (11.7%)         44 (12.2%)         
  HR                      93 (SD 19.7)       98 (SD 22.5)       0.02
  SBP                     138 (SD 25.8)      139 (SD 27.1)      NS
  DBP                     74 (SD 14.1)       76 (SD 16.0)       NS
  T                       36.7 (SD 0.9)      36.6 (SD 0.9)      NS
  ICU                     1 (SD 0.4)         13 (SD 3.6)        0.01
  MV                      2 (0.8%)           14 (3.9%)          0.02
  NIMV                    23 (9.6%)          67 (18.5%)         0.003
  Leukocytes              10,831 (SD 4780)   11,675 (SD 5174)   0.04
  Neutrophils (%)         75.2 (SD 13.8)     77.7 (SD 12.2)     0.02
  Eosinophils (%)         2.2 (SD 13.5)      1.3 (SD 3.1)       NS
  Glucose                 135 (SD 53.3)      143 (SD 60.3)      NS
  Urea                    47 (SD 21.9)       55 (SD 33.9)       0.001
  Creatinine              2.2 (SD 13.5)      1.3 (SD 3.1)       NS
  Hyponatremia            15 (6.4%)          49 (13.6%)         0.005
  K+                      4.4 (SD 0.4)       4.5 (SD 0.8)       0.01
  Albumin                 3.8 (SD 0.4)       3.7 (SD 1.8)       NS
  Fibrinogen              553 (105.8)        537 (123.4)        NS
  CRP                     54 (79.8)          68 (113.1)         NS
  Troponin (+)            18 (8.7%)          51 (14.6%)         0.01
  PO~2~                   57 (SD 14.8)       62 (SD 29.0)       0.009
  PCO~2~                  44 (SD 10.6)       47 (SD 14)         0.001
  CO~3~H^−^               28.2 (SD 6.1)      28.6 (SD 5.5)      NS
  PH                      7.4 (SD 0.0)       7.3 (SD 16.2)      NS
  Pneumonia XR            37 (15.5%)         96 (26.8%)         0.001
  Pleural effusion XR     23 (9.7%)          50 (14%)           NS

CRP: C-reactive protein; DBP: diastolic blood pressure; HR: heart rate; ICU: intensive care unit; K+: potassium; MV: mechanical ventilation; NIMV: non-invasive mechanical ventilation; NS: not significant; SBP: systolic blood pressure; T: temperature; XR: chest X-ray.
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###### 

General and clinical characteristics of patients with and without hyponatremia.

  Variables                         WITHOUT Hyponatremia   WITH Hyponatremia   *p*
  --------------------------------- ---------------------- ------------------- -------
  Age n (SD)                        73.9 (10.6)            73.4 (10.6)         NS
  Male                              460 (86%)              56 (86.2%)          NS
  BMI n (SD)                        28.5 (5.8)             27.4 (4.7)          NS
  FEV1% n (SD)                      52.5 (18.9)            55.6 (19.7)         NS
  Comorbidities                                                                
  AF                                134 (25%)              27 (41.5%)          0.005
  Cognitive impairment              33 (6.2%)              0 (0.0%)            0.04
  Anemia                            68 (12.7%)             14 (21.5%)          0.05
  Hyponatremia-inducing drugs       249 (46.5)             37 (56.9%)          NS
  Admissions previous year n (SD)   0.8 (1.3)              0.9 (1.6)           NS
  Exacerbations previous year       1.2 (1.8)              1.4 (2.5)           NS
  Pleural effusion XR               59 (11.1%)             14 (21.9%)          0.01
  Leukocytes n (SD)                 11,160 (4897)          12,623 (5878)       0.02
  CRP n (SD)                        56 (82.7)              109 (185.4)         0.05
  Hospital mortality                14 (2.6%)              3 (4.6%)            NS
  Prolonged stay                    282 (52.7%)            45 (69.2%)          0.01
  Readmission within 30 days        84 (15.7%)             7 (10.8%)           NS
  Poor progress                     313 (58.5%)            48 (73.8%)          0.01

AF: atrial fibrillation; BMI: body mass index; CRP: C-reactive protein; FEV1%: Tiffeneau--Pinelli index; NS: not significant; XR: chest X-ray.
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###### 

Hyponatremia-related factors.

  Multivariate Analysis                         
  ----------------------- ------ -------------- ----------
  AF                      1.95   (1.12; 3.41)   0.01
  Pleural effusion        2.01   (1.03; 3.94)   0.04
  Prolonged stay          1.79   (1.01; 3.15)   \<0.0001

AF: atrial fibrillation. Adjusted by: AF, Anemia, Cognitive impairment, Pleural effusion XR, Leukocytes, CPR, Prolonged stay, Poor progress.
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###### 

Factors related to poor progress following admission for AECOPD.

  Multivariate Analysis                         
  ----------------------- ------ -------------- -------
  Home O~2~               0.35   (0.16; 0.74)   0.006
  Pneumonia               1.84   (1.05; 3.24)   0.03
  Hyponatremia            3.68   (1.57; 8.58)   0.003

Adjusted by: Etiology of exacerbation, Mechanical ventilation, Non-invasive mechanical ventilation, Flu-vaccinated, GOLD, Baseline dyspnea, AF, CHF, CKD, Baseline treatment (SABA, Oral corticosteroids, SAMA, Theophylline, Azithromycin, Acetylcysteine, Phosphodiesterase inhibitors), Home O~2~, Pneumonia XR, Positive Troponin, Hyponatremia, HR, Admission at ICU, Leukocytes, Neutrophils (%), Urea, Potassium, PO~2~, PCO~2~.
